

Advanced Proteome Therapeutics Corp.

00:38 30 Jan 2014

Advanced Proteome Therapeutics to progress two anti-cancer agents to further animal testing after encouraging results

Advanced Proteome Therapeutics (CVE:APC) has discovered that two molecules from the first series of potential anti-cancer agents it is testing have shown "statistically significant retardation" of tumour growth in mice.

The drug development company recently prepared several molecules using its patent-pending technologies, representing the first of several series it is conceiving as potential anti-cancer agents.

Advanced Proteome is developing a potential three-in-one cancer treatment that acts as a targeted, combination and homogeneous therapy all in a single agent. The company modifies proteins to attach known therapeutics to specific sites, designed to boost the properties of the proteins targeted for the specific cancer cells and giving them additional therapeutic abilities.

The unique protein is used not just as a delivery vehicle to the tumour cells, but also as a scaffold on which to attach each anti-cancer entity to its own specific site on the protein surface -- key to efficient manufacturing and product development. The goal is to activate the immune system to attack and help rid the body of the tumour cells.

The company said that each of the molecules prepared in the first series has its own individual attributes for drug development. In the first round of tests conducted by APC and its collaborators, all members of the first series showed a "high affinity for specific cancer cells", APC said, with no obvious toxic effects on healthy cells.

The unmodified protein by itself also showed the ability to "retard" tumour growth and a conjugate of the protein prepared by the company was shown to concentrate in tumours.

Following on from these tests, the preliminary results of which were announced in December, the company said it has now discovered that two members of the first series have shown "statistically significant retardation" of tumour growth in mice and have a higher affinity than the unmodified protein toward specific cancer cells.

This suggests that APC's chemical modifications to the protein can be used to boost the protein's activity, which in unmodified form activates animal immune systems to destroy tumour cells. The drug developer has selected these two members for further testing in animal models of cancer, it said.

APC is planning to select a lead member from at least three series of protein conjugates, in an effort to develop the most "effective and commercially attractive" candidate with the best mix of properties. Testing has now begun on the second series, with the third series of tests to begin shortly.

Price: 0.13

Market Cap: \$3.47 m

1 Year Share Price Graph



Share Information

Code: APC

Listing: TSX-V

52 week	High	Low
	0.19	0.035

Sector: Pharma & Biotech

Website: www.advancedproteome.com

Company Synopsis:

Advanced Proteome's vision is to advance the field of protein-site targeting to deliver more effective and personalized cancer therapies faster, accelerate improvement in survival rates, while creating value for all stakeholders. The company plans to fulfill this vision by boldly creating protein therapeutics that carry multiple entities targeted for specific cancer cells.

action@proactiveinvestors.com.au

While animal testing is carried out, the company will at the same time seek corporate partners in the pharmaceutical industry for joint work or licensing deals, which would help advance its candidates toward clinical trials.

Site specific modification technology is regarded as key to avoiding heterogeneous mixtures that can compromise biological activity, complicate manufacturing and production processes, and give rise to unwanted toxicities.

The Vancouver-based company last year signed agreements to test its anti-cancer protein conjugates on a pre-clinical basis with the Stanford University School of Medicine and the University of Iowa.

Year-to-date, APC's stock has advanced 60%, closing on Tuesday at 32 cents on the TSX Venture Exchange.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 action@proactiveinvestors.com.au

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.